Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-12-01T09:05:20.689Z Has data issue: false hasContentIssue false
  • English
  • Français

Risk Factors for Peak Dose Dyskinesia in 100 Levodopa-treated Parkinsonian Patients

Published online by Cambridge University Press:  18 September 2015

Pierre J. Blanchet ,
Pierre Allard ,
Laurent Grégoire ,
François Tardif  and
Paul J. Bédard
Pierre J. Blanchet
Affiliation:
Neurobiology Research Centre, Hôpital de l’Enfant-Jésus, Canada
Pierre Allard
Affiliation:
Epidemiology Research Unit. Hôpital du Saint-Sacrement, Québec City (Québec), Canada
Laurent Grégoire
Affiliation:
Neurobiology Research Centre, Hôpital de l’Enfant-Jésus, Canada
François Tardif
Affiliation:
Neurobiology Research Centre, Hôpital de l’Enfant-Jésus, Canada
Paul J. Bédard*
Affiliation:
Neurobiology Research Centre, Hôpital de l’Enfant-Jésus, Canada
*
Neurobiology Research Centre, Hôpital de l’Enfant-Jésus, 1401, 18e Rue, Québec City (Quebec), Canada GIJ 1Z4
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: No clinical parameter other than “sufficient” dopamine denervation and exposure to exogenous levodopa has been unquestionably linked to dyskinesia in levodopa-treated Parkinson’s disease patients. Methods: We retrospectively analyzed data on 100 consecutive patients treated with levodopa for 1 to 18 years to identify clinical risk factors for dyskinesia. The cumulative dyskinesia-free survival probability in relation to levodopa therapy was assessed using the Kaplan-Meier method. Results: Overall, 56% of patients developed dyskinesia after a mean of 2.9 years, a figure similar to the average duration of levodopa treatment in the non-dyskinetic group. Dyskinetic patients were significantly younger at disease onset, but their mean latency to dyskinesia induction after levodopa initiation was not different from older dyskinetic individuals and the overall dyskinesia-free survival of younger subjects was not worse either. Dyskinetic patients were on a higher daily levodopa dose than non-dyskinetic subjects when dyskinesia emerged, but the cumulative levodopa dose used prior to dyskinesia did not discriminate dyskinetic from non-dyskinetic patients. A delay in initiating levodopa therapy of more than three years after disease onset and levodopa treatment initiation in Hoehn-Yahr stage II compared to stage I patients did not increase the probability of developing dyskinesia over time. Conclusions: Since withholding levodopa therapy did not increase the risk for dyskinesia in our patients and can delay the emergence of dyskinesia after onset of parkinsonian symptom, a trial with a dopaminomimetic agonist as initial treatment appears logical.

Résumé

Résumé

Facteurs de risque de l’apparition de dyskinésies chez 100 patients parkinsoniens traités par la lévodopa. Introduction: Le profil clinique du parkinsonien à risque de développer des dyskinésies sous L-dopa demeure controversé. Une dénervation dopaminergique et une exposition à la L-dopa “suffisantes” ne peuvent identifier les sujets susceptibles. Méthode: Par une analyse rétrospective des dossiers de 100 patients traités par la L-dopa pendant au moins un an, nous avons tenté d’identifier des facteurs de risque favorisant l’apparitiende dyskinésies. La méthode de Kaplan-Meier a permis de comparer la probabilité de sous-groupes de sujets de demeurer sans dyskinésie en fonction de la durée de la dopalhérapie. Résultats: La proportion de sujets dyskinétiques dans cette population a atteint 56%. le délai moyen d’induction de dyskinésies après le début du traitement par la L-dopa a été de 2.9 années, une valeur non discriminante car semblable à la durée moyenne de traitement de nos sujets non dyskinétiques. Les patients dyskinétiques étaient statistiquement plus jeunes au moment de l’apparition des premiers signes parkinsoniens. Toutefois, le délai d’induction de dyskinésies et la survie globale sans dyskinésie chez les sujets jeunes n’étaient pas différents de ceux des sujets plus âgés. La dose quotidienne de L-dopa administrée au moment de l’apparition de dyskinésies était en moyenne plus élevée que celle des sujets non dyskinétiques mais la dose cumulative de L-dopa avant l’apparition de dyskinésies était semblable pour les deux groupes. L’introduction de la L-dopa plus de trois ans après le début des symptômes parkinsoniens ou au stade Hoehn-Yahr II plutôt que I n’a pas été associée à une probabilité accrue de développer des dyskinésies en cours de dopathérapie. La dyskinésie est un phénomène précoce dont le processus d’induction n’est pas accéléré par une dopathérapie introduite plus tardivement. Conclusion: Les auteurs concluent qu’il est souhaitable de tenter un traitement avec un agoniste dopaminergique dans les stades initiaux de la maladie de Parkinson afin de retarder l’apparition de dyskinésies après le début du syndrome parkinsonien, en particuler chez les sujets jeunes.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 23 , Issue 3 , August 1996 , pp. 189 - 193
Copyright
Copyright © Canadian Neurological Sciences Federation 1996

References

1. Cotzias, GC., Van Woert, MH., Schiffer, LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374–379.CrossRefGoogle ScholarPubMed
2. Nutt, JG. Levodopa-induced dyskinesia: Review, observations, and speculations. Neurology 1990; 40: 340–345.Google Scholar
3. Crossman, AR., Clarke, CE., Boyce, S., Robertson, RG., Sambrook, MA. MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms. Can J Neurol Sci 1987; 14: 428–435.Google Scholar
4. Bédard, PJ., Gomez-Mancilla, B., Blanchette, P., et al. Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey model tell us? Can J Neurol Sci 1992; 19: 134–137.Google Scholar
5. Filion, M., Tremblay, L., Bédard, PJ. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 1991; 547: 152–161.Google ScholarPubMed
6. Mitchell, IJ., Boyce, S., Sambrook, MA., Crossman, AR. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain: implications for the neural mechanisms that mediate dopamine agonists-induced dyskinesia. Brain 1992; 115: 809–824.CrossRefGoogle Scholar
7. Crossman, AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa-or dopamine agonist-induced dyskinesia in Parkinson’s disease: implications for future strategies in treatment. Mov Disord 1990; 5: 100–108.Google Scholar
8. Lesser, RP., Fahn, S., Snider, SR., et al. Analysis of the clinical problems in parkinsonisms and the complications of long-term levodopa therapy. Neurology 1979; 29: 1253–1260.Google Scholar
9. Pederzoli, M., Girotti, F., Scigliano, G., et al. L-Dopa long-term treatment in Parkinson’s disease: age-related side effects. Neurology 1983; 33: 1518–1522.Google Scholar
10. Friedman, A. Levodopa-induced dyskinesia: clinical observations. J Neurol 1985; 232: 29–31.Google Scholar
11. Tanner, CM., Kinori, I., Goetz, CG., et al. Age at onset and clinical outcome in idiopathic Parkinson’s disease. Neurology 1985; 35 (Suppl. 1): 276.Google Scholar
12. Quinn, N., Critchley, P., Marsden, CD. Young onset Parkinson’s disease. Mov Disord 1987; 2: 73–91.CrossRefGoogle ScholarPubMed
13. Cedarbaum, JM., Gandy, SE., McDowell, FH. “Early” initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson’s disease. Neurology 1991; 41: 622–629.Google Scholar
14. Wu, RM., Chiu, HC., Wang, M., Chen, RC. Risk factors on the occurrence of response fluctuations and dyskinesias in Parkinson’s disease. J Neural Transiti [P-D Sect] 1993; 5: 127–133.CrossRefGoogle ScholarPubMed
15. Diamond, SG., Markham, CH., Hoehn, MM., et al. Effect of age at onset on progression and mortality in Parkinson’s disease. Neurology 1989; 39: 1187–1190.Google Scholar
16. Horstink, MWIM., Zijlmans, JCM., Pasman, JW., et al. Severity of Parkinson’s disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psychiatry 1990; 53: 224–226.CrossRefGoogle ScholarPubMed
17. Lang, AE., Meadows, JC., Parkes, JD., Marsden, CD. Early onset of the “on-off” phenomenon in children with symptomatic parkinsonism. J Neurol Neurosurg Psychiatry 1982; 45: 823–825.Google Scholar
18. Langston, JW., Ballard, P. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson’s disease. Can J Neurol Sci 1984; 11 (Suppl.): 160–165.Google Scholar
19. Bergmann, KJ., Mendoza, MR., Yahr, MD. Parkinson’s disease and longterm levodopa therapy. In: Yahr, MD., Bergmann, KJ., eds. Advances in Neurology, Vol 45: Parkinson’s disease. New York: Raven Press, 1986: 463–467.Google Scholar
20. Blin, J., Bonnet, AM., Agid, Y. Does levodopa aggravate Parkinson’s disease? Neurology 1988; 38: 1410–1416.CrossRefGoogle ScholarPubMed
21. Hoehn, MMM. Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson’s disease. Acta Neurol Scand 1985; 71: 97–106.Google Scholar
22. Fahn, S., Bressman, SB. Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 1984; 11 (Suppl.): 200–206.CrossRefGoogle ScholarPubMed
23. Klawans, HL., Crossett, P., Dana, N. Effect of chronic amphetamine exposure on stereotyped behavior: implications for pathogenesis of L-Dopa-induced dyskinesias. In: Calne, DB., Chase, TN., Barbeau, A., eds. Advances in Neurology, Vol. 9. New York: Raven Press, 1975: 105–112.Google Scholar
24. Sweet, RD., McDowell, FH. Five years’ treatment of Parkinson’s disease with levodopa. Ann Intern Med 1975: 83: 456–463.Google Scholar
25. Rajput, AH., Stern, W., Laverty, WH. Chronic low-dose levodopa therapy in Parkinson’s disease: an argument for delaying levodopa therapy. Neurology 1984; 34: 991–996.Google Scholar
26. Poewe, WH., Lees, AJ., Stern, GM. Low-dose L-Dopa therapy in Parkinson’s disease: a 6-year follow-up study. Neurology 1986: 36: 1528–1530.Google Scholar
27. Tanner, CM. Drug-induced movement disorders (tardive dyskinesia and dopa-induced dyskinesia). In: Vinken, PJ., Bruyn, GW., Klawans, HL., eds. Handbook of Clinical Neurology, Vol 5(49): Extrapyramidal Disorders. Amsterdam: Elsevier Science, 1986: 185–204.Google Scholar
28. Lawless, JF. Statistical Models and Methods for Lifetime Data. New York: J Wiley & Sons, Eds, 1982.Google Scholar
29. Montastruc, JL., Rascol, O., Senard, JM., Rascol, A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson’s disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994; 57: 1034–1038.CrossRefGoogle ScholarPubMed
30. Peppe, A., Dambrosia, JM., Chase, TN. Risk factors for motor response complications in L-Dopa-treated parkinsonian patients. In: Narabayashi, H., Nagatsu, T., Yanagisawa, N., Mizuno, Y., eds. Advances in Neurology, Vol 60: Parkinson’s disease: from Basic Research to Treatment. New York: Raven Press, 1993: 698–702.Google Scholar
31. Fahn, S., Bressman, SB. Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 1984; 11: 200–206.Google Scholar
32. Rajput, AH., Uitti, RJ. When to use levodopa in parkinsonism. Lancet 1986; 1(8493): 1324–1325.CrossRefGoogle ScholarPubMed
33. Schneider, JS. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 1989; 34: 193–196.CrossRefGoogle ScholarPubMed
34. Wilson, JA., Smith, RG. The prevalence and aetiology of long-term LDopa side-effects in elderly parkinsonian patients. Age and Ageing 1989; 18: 11–16.CrossRefGoogle ScholarPubMed